Selecta Biosciences, Inc. (SELB) News
Filter SELB News Items
SELB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SELB News Highlights
- For SELB, its 30 day story count is now at 3.
- Over the past 14 days, the trend for SELB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MG, AB and GENE are the most mentioned tickers in articles about SELB.
Latest SELB News From Around the Web
Below are the latest news stories about SELECTA BIOSCIENCES INC that investors may wish to consider to help them evaluate SELB as an investment opportunity.
Further weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really... |
Selecta Biosciences Announces Merger with Cartesian Therapeutics– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – |
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiWATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) ( |
The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collabA Watertown biotech trimmed its pipeline again, setting aside all of its experimental drugs except one. It's the second time the company has cut programs this year. Plus other life sciences news you may have missed. |
Q2 2023 Selecta Biosciences Inc Earnings CallQ2 2023 Selecta Biosciences Inc Earnings Call |
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue EstimatesSelecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 46.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conf |
Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26%Key Insights Selecta Biosciences' significant individual investors ownership suggests that the key decisions are... |
10 Best Revenue Growth Stocks to BuyIn this piece, we will take a look at the ten best revenue growth stocks to buy. If you want to skip over the latest news for the stock market and want to jump ahead to the top five stocks in this list, then take a look at 5 Best Revenue Growth Stocks to Buy. […] |
Selecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five yearsIt's nice to see the Selecta Biosciences, Inc. ( NASDAQ:SELB ) share price up 22% in a week. But will that repair the... |